Distribution of GlaxoSmithKline diabetes drug Avandia has been suspended for six months in Saudi Arabia, as links to adverse cardiovascular effects are studied in more detail. The Saudi Food and Drug Authority made the decisio, and called for the pharmaceutical company to provide further evidence before permanent removal.
Diabetes is a major problem in Saudi Arabia, particularly in the more developed areas such as Riyadh. According to the director of the SFDA national drug and poison center, Abdullah Al-Humaidan: “The SFDA Committee for Medicinal Products Registration has given the company six months to provide evidence as to why the drug should not be permanently removed from the Saudi market.”
He went on to further outline concerns about the base chemical in Avandia, rosiglitazone. An is an oral diabetes medicine to help people with type 2 diabetes control their blood sugar levels . As many as 27 per cent of Saudis suffer from diabetes, with the disease spreading at an alarming rate.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…